MicroRNA and hypertension

Zhongguo Zhongyao Zazhi

Volumn 39, Issue 3, 2014, Pages 397-401

  Duan, Lian ^a   Xiong, Xing Jiang ^a   Wang, Jie ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Hypertension; MiRNA; Pathogenesis; Review; Treatment

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

HYPERTENSION; PATHOGENESIS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION; MICRORNAS; MOLECULAR TARGETED THERAPY;

EID: 84897937813     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20140308     Document Type: Review

References (42)

1. Kim V N. MicroRNA biogenesis: coordinated cropping and dicing[J]. Nat Rev Mol Cell Biol, 2005, 6(5): 376.
2. 2011, 11(6): 380.
3. 2013, 21(1): 4.
4. Volinia S, Calin G A, Liu C G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci USA, 2006, 103(7): 2257.
5. Cesare Peschle. MicroRNAs control angiogenesis[J]. Blood, 2006, 108(9): 3068.
6. 2010, 30(5): 453.
7. Yang Z, Kaye D M. Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension[J]. Hum Mutat, 2009, 30(3): 328.
8. Yang Z, Venardos K, Jones E, et al. Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction[J]. Circulation, 2007, 115(10): 1269.
9. Poliseno L, Tuccoli A, Mariani L, et al. MiRNAs modulate the angiogenic properties of HUVECs[J]. Blood, 2006, 108(9): 3068.
10. Cordes K R, Sheehy N T, White M P, et al. MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity [J]. Nature, 2009, 460(7256): 705.
11. 2013, 35(8): 707.
12. Mei Xin, Eric M Small, Lillian B Sutherland, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury[J]. Genes Dev, 2009, 23: 2166.
13. Yu M L, Wang J F, Wang G K, et al. Vascular smooth muscle cell proliferation is influenced by let-7d microRNA and its interaction with KRAS[J]. Cir J, 2011, 75: 703.
14. Chan M C, Hilyard A C, Wu C, et al. Molecular basis for antagonism betweenpdgf and the tgf beta family of signalling pathways by control of mir-24expression[J]. EMBO J, 2010, 29: 559.
15. Leeper N J, Raiesdana A, Kojima Y, et al. Microma-26a is a novel regulator of vascular smooth muscle cell function[J]. J Cell Physiol, 2011, 226(4): 1035.
16. Sethupathy P, Borel C, Gagnebin M, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes[J]. Am J Hum Genet, 2007, 81(2): 405.
17. Martin M M, Lee E J, Buckenberger J A, et al. MicroRNA-155 regulates human angiotensinIItype1 receptor expression in fibroblasts[J]. J Biol Chem, 2006, 281(27): 18277.
18. Mottl A K, Shoham D A, North K E. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a huge review[J]. Genet Med, 2008, 10(8): 560.
19. Yael Nossent A, Hansen J L, Doggen C, et al. SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction[J]. Am J Hypertens, 2011, 24(9): 999.
20. + metabolism[J]. Proc Natl Acad Sci USA, 1998, 95(16): 9424.
21. Söber S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression[J]. Biochem Biophys Res Commun, 2010, 391(1): 727.
22. Sándor Bátkai, Thomas Thum. MicroRNAs in hypertension: mechanisms and therapeutic targets[J]. Curr Hypertens Rep, 2012, 14: 79.
23. 2010, 24(2): 172.
24. Mitchell P S, Parkin R K, KrohE M, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci USA, 2008, 105(30): 10513.
25. Li Shuqiang, Zhu Jianguo, Zhang Weili, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection[J]. Circulation, 2011, 124: 175.
26. 2011.
27. Karolina D S, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome[J]. J Clini Endocrinol Metabol, 2012, 97(12): 2271.
28. 2011, 19(6): 549.
29. Fiedler J, Jazbutyte V, Kirchmaier B C, et al. MicroRNA-24 regulates vascularity after myocardial infarction[J]. Circulation, 2011, 124(6): 720.
30. 2013, 30(7): 785.
31. 2007, 2(1): 3.
32. 2012, 27(11): 2862.
33. 2013, 38(8): 1251.
34. Wang J, Xiong X J. Current situation and perspectives of clinical study in integrative medicine in China[J]. Evid-Based Complement Alternat Med, 2012, doi: 10.1155/2012/268542.
35. Wang J, Xiong X J. Control strategy on hypertension in Chinese medicine [J]. Evid-Based Complement Alternat Med, 2012, doi: 10.1155/2012/284847.
36. 2011, 52(23): 1985.
37. 2013, 38(9): 1277.
38. 2013, 38(11): 1836.
39. Xiong X J, Yang X C, Liu Y M, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science[J]. Hypert Res, 2013, doi: 10.1038/hr.2013.18.
40. Xiong X J, Yang X C, Liu W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine [J]. Evid-Based Complement Alternat Med, 2013, doi: 10.1155/2013/275279.
41. Wang J, Xiong X J. Evidence-based Chinese medicine for hypertension[J]. Evid-Based Complement Alternat Med, 2013, doi: 10.1155/2013/978398.
42. Wang J, Xiong X J. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews[J]. Evid-Based Complement Alternat Med, 2012, doi: 10.1155/2012/697237.